Albumin Market Size to Hit 8.76 Billion by 2030; Growing Network of Plasma Fractionation Facilities to Boost Market Progress

The global albumin market size touched USD 6.14 billion in 2022 and is predicted to reach USD 6.35 billion in 2023. The market is anticipated to touch USD 8.76 billion by 2030, recording a CAGR of 4.7% over 2023-2030.

Fortune Business Insights™ presents this information in its latest report titled “Albumin Market Size, Share & COVID-19 Impact Analysis, By Product (Human Serum Albumin, Recombinant Albumin, and Bovine Serum Albumin), By Application (Therapeutics, Diagnostics, and Research), By End-user (Hospital & Clinics, Pharmaceutical & Biotechnology Industry, and Research Institutes), and Regional Forecast, 2023-2030”.

Albumin is a form of protein made by the liver that is abundantly found in the plasma. This protein plays a key role in stabilizing the osmotic pressure of the blood. Factors, such as expansion of plasma fractionation facilities and rising incidence of hypoalbuminemia are expected to bolster the albumin market growth.

Growth in Medical Research & Development Activities During COVID-19 Fueled Market Expansion

The COVID-19 outbreak had a favorable impact on the market progress as medical researchers increased their research & development activities to find out and prove the effects of albumin on COVID-19-positive patients. Many leading companies in the market saw a major rise in their revenue from the albumin segment due to the pandemic as the demand for albumin-based products increased considerably.

Sartorius AG and CGT Catapult Forge Alliance to Revolutionize Therapy Manufacturing

In June 2023, Sartorius AG (ALBUMEDIX) partnered with Cell and Gene Therapy Catapult (CGT Catapult) to explore utilizing its albumin-based solutions in cutting-edge therapy applications, notably viral vector production. This collaboration aims to advance the efficacy of advanced therapies through innovative manufacturing techniques.

Growing Network of Plasma Fractionation Facilities to Boost Market Progress

The rising use of plasma in the drug development process has fostered the expansion of plasma fractionation facilities. Many nations, such as Italy, Australia, and Spain are increasing their network of these facilities to keep up with the growing demand for plasma among pharmaceutical companies. Fractionation facilities help split plasma into albumin and other components.

However, strict government regulations in several countries may stifle market growth.

Takeda, Grifols, S.A., and CSL Behring to Lead Market Growth Due to Vast Product Portfolios

Companies, such as Grifols, S.A., Takeda Pharmaceutical Co. Ltd., and CSL Behring (CSL) are dominating the market as they have an expansive product range that cater to unique needs of their customers. These companies are focusing on getting the approval for their novel products from reputed regulatory agencies and entering partnerships and mergers to expand their presence.

Notable Industry Development:

• January 2022: InVitria obtained the regulatory approval for Exbumin, a recombinant human serum albumin, which will be used as an excipient in vaccines to enhance potency and stability. The product was approved as an excipient in a vaccine that will be used in Europe, the U.K., Japan, and the U.S. Obtaining the regulatory approval helped the company increase its footprint in the global market.

List of the Companies Profiled in the Report:

• CSL Behring (CSL), (U.S.)


• Kedrion S.p.A. (Italy)


• Takeda Pharmaceutical Company Limited (Japan)


• Lazuline Bio (India)


• InVitria (U.S.)


• Biorbyt Ltd. (U.K.)


• Grifols, S.A. (Spain)


• Octapharma AG (Switzerland)


• Albumin Bioscience (U.S.)


• Aspira Chemical (U.S.)


• ALBUMEDIX (Sartorius AG) (Germany)


• Cyagen Biosciences (U.S.)


• Merck KGaA (Germany)


• Thermo Fisher Scientific Inc. (U.S.)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/albumin-market-102637

Further Report Findings

• Asia Pacific dominated the global albumin market share in 2022 as there is a strong demand for plasma-based therapeutics in various countries across the region, especially China. The country is also expanding its production capacity to cater to the growing demand for plasma-based products.


• Europe is expected to record a major CAGR during the forecast period as key players across the region are implementing various strategies, such as mergers, partnerships, and establishment of plasma fractionation facilities. These strategies will increase their product portfolios.


• Based on product, the human serum segment dominated the market in 2022 as companies across the world are launching a wide range of new and advanced products. Moreover, the sales of drugs that are used to treat hypoalbuminemia have also skyrocketed in recent years, which will further fuel the segment’s growth.

Table of Segmentation